IndraLab

Statements

USP13 inhibits MCL1. 2 / 2
| 2
reach
"Hence, pharmaceutical intervention of USP13 activity is expected to antagonize the tumorigenic potential of MCL1 oncoprotein, and combined administration of USP13 inhibitors with clinically approved venetoclax therapy may represent a promising targeting strategy for the treatment of human cancer by inducing tumor cell death."
29335437
reach
"Usp13 knockdown obviously reduces MCL1 protein abundance and significantly increases the sensitivity of tumor cell to BH3 mimetic inhibitors targeting BCL-2 and BCL-XL [ 57 ]."
33508399